Tags : Pan-JAK Inhibitor Program

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for

Shots: Theravance to receive $10M up front, up to $240M development & commercial milestones with royalties on global sales of any product developed from the program. Pfizer to get a global license for Theravance’s skin-targeted, LA, pan-Janus kinase (JAK) inhibitors   Pfizer will validate Theravance’s expertise in the discovery & development of organ-selective JAK inhibitors […]Read More